Ibrutinib Adapted to Response in Patients With CLL

NCT05360758 · clinicaltrials.gov ↗

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

OTHER: Evaluation of response to treatment with response-tailored Ibrutinib in patients with chronic lymphocytic leukemia

Sponsor

Grupo Argentino de Tratamiento de la Leucemia Aguda